

**ROLE OF HELICOBACTER BACTERIA IN  
COLITIS AND COLO-RECTAL NEOPLASMS  
HISTOPATHOLOGICAL AND  
IMMUNOHISTOCHEMICAL STUDY**

*Thesis*

Submitted for partial fulfillment of M.Sc. degree in Pathology

*Presented By*

**Ahmed Naeem Mohamed Eesa**  
*(M.B.B.Ch.)*

*Supervised by*

**Prof. Dr. Samia Mohamed Gabal**

Professor of Pathology

Faculty of Medicine – Cairo University

**Assis. Prof. Dr. Hala Naguib Hosni**

Assistant professor of Pathology

Faculty of Medicine – Cairo University

**Dr. Samar Abd El-Monem El- Sheikh**

Lecturer of Pathology

Faculty of Medicine – Cairo University

**Faculty of Medicine**

**Cairo University**

**2012**



﴿ قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا  
عَلَّمْتَنَا إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ ﴾

(البقره ٣٢)

صدق الله العظيم

## ACKNOWLEDGEMENTS

I would like to express my profound gratitude and immense appreciation to Prof Dr. Samia Mohamed Gabal, professor of Pathology, Cairo University, for her keen interest in the progress of this work, her constructive criticism as well as her great patience in reading and revising the manuscripts. She was very generous in providing me with her knowledge and scientific materials.

Sincere thanks are due to Prof Dr. Kala Maquib Hosni, assistant professor of Pathology, Cairo University, for her helpful suggestions and valuable advice.

Special thanks are due to Dr. Samar Abd El-Monem El-Sheikh, lecturer of Pathology Cairo University, for her great assistance.

I must thank the team of the laboratories of Pathology Department, Cairo University Hospitals for their help in carrying out laboratory investigations of patients under study.

## ABSTRACT

This study aims to determine the role of *Helicobacter* organisms in the development of colitis or colorectal neoplasia and to correlate *Helicobacter* immunohistochemical positivity with other clinicopathologic parameters. This retrospective study was conducted on fifty cases, including 10 (20%) cases of normal colon, 15 (30%) cases of colitis, 10 (20%) cases of colonic tubular adenoma and 15 (30%) cases of colorectal carcinoma. Immunohistochemical detection method rather than routine histochemistry with Giemsa was used for the detection of *H. pylori*. This study showed that:

- Anti-*H. Pylori* antibodies were positive in 14 (28%), however 36 (72%) were negative.
- Among normal participants, anti- *H. Pylori* antibody staining was positive in 2 (20%) and negative in 8 (80%).
- Among patients with colitis, anti- *H. Pylori* antibody staining was positive in 5 (33.3%) and negative in 10 (66.7%).
- Among patients with adenoma, anti- *H. Pylori* antibody staining was positive in 4 (40%) and negative in 6 (60%).
- Among patients with carcinoma, anti- *H. Pylori* antibody staining was positive in 3 (20%) and negative in 12 (80%).
- The prevalence of *H. Pylori* positivity is not statistically significant in cases of normal colon, colitis, tubular adenoma or carcinoma.
- However risk estimation as determined by Odds ratio showed that *H. Pylori* positivity is most likely present in specimens with colitis (**Odds ratio = 1.444**) and adenoma (**Odds ratio= 2.000**).

**Keywords: ( *Helicobacter* bacteria – Colitis – Colorectal neoplasms – Immunohistochemistry )**

# CONTENTS

	Page
<b>ACKNOWLEDGEMENTS .....</b>	<b>ii</b>
<b>LIST OF ABBREVIATIONS .....</b>	<b>iii</b>
<b>LIST OF FIGURES .....</b>	<b>vi</b>
<b>LIST OF TABLES .....</b>	<b>ix</b>
<b>ABSTRACT .....</b>	<b>x</b>
<b>INTRODUCTION AND AIM OF THE WORK .....</b>	<b>1</b>
<b>REVIEW OF LITERATURE .....</b>	<b>5</b>
I. Anatomy of the Colon .....	5
II. Colitis .....	15
III. Colorectal Neoplasms .....	37
IV. Helicobacter Pylori .....	96
<b>MATERIALS AND METHODS .....</b>	<b>108</b>
<b>RESULTS .....</b>	<b>113</b>
<b>DISCUSSION .....</b>	<b>136</b>
<b>SUMMARY.....</b>	<b>140</b>
<b>CONCLUSION .....</b>	<b>143</b>
<b>RECOMMENDATION .....</b>	<b>144</b>
<b>REFERENCES .....</b>	<b>145</b>
<b>ARABIC SUMMARY .....</b>	

## LIST OF ABBREVIATIONS

AC I	Amsterdam Criteria I
ACF	Aberrant Cryptic Foci
AJCC	American Joint Comitee on Cancer
APC	Adenomatous Polyposis Coli
BAX	Bcl-2–associated X protein
CD	Crohn’s Disease
CEA	Carcinoembryonic Antigen
CMV	Cytomegalovirus
c-myc	Oncogene
CRC	Colorectal Carcinoma
CRM	Circumfrential Resection Margin
CTC	Computed Tomographic Colonography
DALM	Dysplasia Associated Lesion or Mass
DCBE	Double Contrast Barium Enema
DCC gene	Deleted in colon cancer Gene
DNA	Deoxyribonucleic acid
EHEC	Enterohemorrhagic <i>E. coli</i>
EIEC	Enteroinvasive <i>E. coli</i>
FAP	Familial Adenomatous Polyposis
FOBT	Focal Occult Blood Test
FSIG	Flexible Sigmoidoscopy
GIT	Gastrointestinal Tract
<i>H.Pylori</i>	Helicobacter Pylori
HNPCC	Hereditary Non-polypsis Colorectal Cancer
HSP	Henoch Shonlein Purpura
IBD	Inflammatory Bowel Disease
IGF2	Insulin-like growth factor 2
K-ras	Oncogene

LOH	Loss of Heterozygosity
MAC	Mucinous Adenocarcinoma
MAP kinase	Mitogen-activated protein kinase
MMP7	Matrix Metalloproteinase 7
NEC	Necrotizing Enterocolitis
NEC	Neuroendocrine Carcinoma
NET	Neuroendoendocrine Tumour
P16	Tumor suppressor gene
P53	Tumor suppressor gene
PMNs	Polymorph Nuclear Leucocytes
PPARs	Peroxisome proliferator-activated receptors
SCC	Squamous Cell Carcinoma
SMAD4	Tumor suppressor
TGF- $\beta$	Transforming growth factor beta
TGF $\beta$ R-II	Transforming growth factor beta receptor-II
TME	Total Mesorectal Excision
UC	Ulcerative Colitis
UICC	Union International Contre Le Cancer
WHO	World Health Organization



## LIST OF FIGURES

<b>No.</b>	<b>Description</b>	<b>Page</b>
<b>Fig. (1)</b>	Sections of the large bowel.	5
<b>Fig. (2)</b>	Arterial supply and venous drainage of the large bowel	10
<b>Fig. (3)</b>	Regional lymph nodes of the large bowel	12
<b>Fig. (4)</b>	Colonic crypt organization	13
<b>Fig. (5)</b>	Opened small bowel in a patient with Crohn's disease	21
<b>Fig. (6)</b>	A Crohn's stricture of the ileum	22
<b>Fig. (7)</b>	Cobblestone change of the mucosa of the terminal ileum in a patient with Crohn's disease	23
<b>Fig. (8)</b>	Mucosal pseudopolyps (inflammatory pseudopolyps) of the terminal ileum in a patient with Crohn's disease	23
<b>Fig. (9)</b>	Submucosal involvement by lymphoid aggregates in Crohn's disease, and marked expansion/duplication of the muscularis mucosae, indicative of previous full-thickness mucosal injury	24
<b>Fig. (10)</b>	A crypt abscess demonstrating active, neutrophilic, inflammation in Crohn's disease	25
<b>Fig. (11)</b>	A granuloma in the mucosa of a case of Crohn's disease.	26
<b>Fig. (12)</b>	Aphthoid ulcer overlying a Peyer's patch in the terminal ileum of a patient with Crohn's disease	27
<b>Fig. (13)</b>	Deep knifelike, fissuring, transmural ulcer in Crohn's disease	27
<b>Fig. (14)</b>	Ulcerative colitis specimen showing hyperaemic mucosa and linear ulcers	28
<b>Fig. (15)</b>	Chronic architectural changes in ulcerative colitis (UC),	29
<b>Fig. (16)</b>	Basal plasmacytosis. Plasma cells separate the crypt bases from the muscularis mucosae	30

<b>Fig. (17)</b>	High-power view of a crypt abscess shows the crypt to be dilated and filled with neutrophils and debris	31
<b>Fig. (18)</b>	Low-grade glandular dysplasia in a patient with longstanding ulcerative colitis	32
<b>Fig. (19)</b>	High-grade dysplasia, showing significant cytologic atypia, with rounding of the nuclei and a greater degree of pseudostratification	33
<b>Fig. (20)</b>	Colonic polyp	37
<b>Fig. (21)</b>	Genetic model of colorectal carcinogenesis	50
<b>Fig. (22)</b>	Adenoma-carcinoma sequence of colorectal cancer	51
<b>Fig. (23)</b>	Colorectal cancer staging	78
<b>Fig. (24)</b>	<i>H.pylori</i> structure	97
<b>Fig. (25)</b>	Colonic biopsy (serial sections)	100
<b>Fig. (26)</b>	Distribution of the study group according to colonic biopsy results.	113
<b>Fig. (27)</b>	Distribution of cases with colorectal cancer according to the site of involvement	115
<b>Fig. (28)</b>	Distribution of cases with colorectal cancer according to the size of the lesion.	115
<b>Fig. (29)</b>	Distribution of cases with colorectal cancer according to their gross pattern.	116
<b>Fig. (30)</b>	Distribution of cases with colorectal cancer according to their histologic type.	117
<b>Fig. (31)</b>	Distribution of cases with colorectal cancer according to their histologic grade.	118
<b>Fig. (32)</b>	Distribution of cases with colorectal cancer according to the depth of tumour invasion.	119
<b>Fig. (33)</b>	Distribution of cases with colorectal cancer according to Duke's stage.	120
<b>Fig. (34)</b>	Anti- <i>H. Pylori</i> antibody staining among the study group.	121

<b>Fig. (35)</b>	Distribution of anti- <i>H. Pylori</i> antibody staining among each group.	123
<b>Fig. (36)</b>	Positive staining for Anti <i>H.pylori</i> antibody in a case of normal colon (800X)	128
<b>Fig. (37)</b>	H&E picture for the previous case (200X)	128
<b>Fig. (38)</b>	Negative staining for Anti <i>H.pylori</i> antibody in a case of normal colon (800X)	129
<b>Fig. (39)</b>	H&E picture for the previous case (200X)	129
<b>Fig. (40)</b>	Positive staining for Anti <i>H.pylori</i> antibody in a case of colitis (800X)	130
<b>Fig. (41)</b>	H&E picture for the previous case (200X)	130
<b>Fig. (42)</b>	Negative staining for Anti <i>H.pylori</i> antibody in a case of colitis (800X)	131
<b>Fig. (43)</b>	H&E picture for the previous case (200X)	131
<b>Fig. (44)</b>	Positive staining for Anti <i>H.pylori</i> antibody in a case of tubular adenoma (800X)	132
<b>Fig. (45)</b>	H&E picture for the previous case (200X)	132
<b>Fig. (46)</b>	Negative staining for Anti <i>H.pylori</i> antibody in a case of tubular adenoma (800X)	133
<b>Fig. (47)</b>	H&E picture for the previous case (200X)	133
<b>Fig. (48)</b>	Positive staining for Anti <i>H.pylori</i> antibody in a case of colorectal carcinoma (800X)	134
<b>Fig. (49)</b>	H&E picture for the previous case (200X)	134
<b>Fig. (50)</b>	Negative staining for Anti <i>H.pylori</i> antibody in a case of colorectal carcinoma (800X)	135
<b>Fig. (51)</b>	H&E picture for the previous case (200X)	135

# LIST OF TABLES

No.	Description	Page
<b>Table (1)</b>	Regional lymph nodes for each segment of the large bowel	11
<b>Table (2)</b>	Genetic changes associated with CRC development	48
<b>Table (3)</b>	Risk factors for colorectal cancer.	55
<b>Table (4)</b>	Familial risk and colon cancer	57
<b>Table (5)</b>	Features of HNPCC	58
<b>Table (6)</b>	Revised diagnostic criteria for HNPCC (Amsterdam criteria II)	59
<b>Table (7)</b>	WHO histological classification of tumours of the colon and rectum	67
<b>Table (8)</b>	WHO histological classification of tumours of the colon and rectum	73
<b>Table (9)</b>	Histopathologic grading systems in colorectal carcinoma	75
<b>Table (10)</b>	TNM classification of tumours of the colon and rectum.	77
<b>Table (11)</b>	TNM stage grouping of tumours of the colon and rectum.	78
<b>Table (12)</b>	Recommended options for colorectal cancer screening in asymptomatic, average-risk individuals.	93
<b>Table (13)</b>	Enterohepatic <i>Helicobacter</i> taxa	103
<b>Table (14)</b>	Distribution of the study group according to diagnosis	113
<b>Table (15)</b>	Distribution of patients according to gender	114
<b>Table (16)</b>	Distribution of cases with colorectal cancer according to the site of involvement.	114
<b>Table (17)</b>	Distribution of cases with colorectal cancer according to the size of the lesion.	115
<b>Table (18)</b>	Distribution of cases with colorectal cancer according to their gross pattern.	116
<b>Table (19)</b>	Distribution of cases with colorectal cancer according to their histologic type.	117
<b>Table (20)</b>	Distribution of cases with colorectal cancer according to their histologic grade.	118

<b>Table (21)</b>	Distribution of cases with colorectal cancer according to the depth of tumour invasion.	119
<b>Table (22)</b>	Distribution of cases with colorectal cancer according to lymph node metastasis.	120
<b>Table (23)</b>	Distribution of cases with colorectal cancer according to Duke's stage.	120
<b>Table (24)</b>	Anti- <i>H. Pylori</i> antibody staining among the study group	121
<b>Table (25)</b>	Distribution of anti- <i>H. Pylori</i> antibody staining among each group.	122
<b>Table (26)</b>	Correlation between normal subjects on colonic biopsy and <i>H. Pylori</i> positivity among the study group	124
<b>Table (27)</b>	Risk estimation of <i>H. Pylori</i> positivity among subjects with normal colonic biopsy.	124
<b>Table (28)</b>	Correlation between colitis on colonic biopsy and <i>H. Pylori</i> positivity among the study group	125
<b>Table (29)</b>	Risk estimation of <i>H. Pylori</i> positivity among subjects with colitis on colonic biopsy.	125
<b>Table (30)</b>	Correlation between adenoma on colonic biopsy and <i>H. Pylori</i> positivity among the study group	126
<b>Table (31)</b>	Risk estimation of <i>H. Pylori</i> positivity among subjects with adenoma on colonic biopsy.	126
<b>Table (32)</b>	Correlation between carcinoma and <i>H. Pylori</i> positivity among the study group	127
<b>Table (33)</b>	Risk estimation of <i>H. Pylori</i> positivity among subjects with carcinoma on colonic biopsy	127

# INTRODUCTION

The number of species in the genus *Helicobacter* has rapidly expanded over the past decade. The genus now includes at least 24 formally named species as well as numerous other helicobacters awaiting formal naming (**Fox, 2002**).

*Helicobacter pylori* (*H.pylori*) is the best known and the most important in terms of global impact on human disease. It infects 50% of the world population and its prevalence varies widely in different parts of the world with average rates of 40–50% in western countries, rising to >90% in the developing world (**Peek and Blaser, 2002**).

*H.pylori* is a Gram-negative bacterium that has become well adapted to the human stomach via interaction with gastric epithelial cells (**De Luca and Iaquinto, 2004**). Chronic gastric infection with *H. pylori* causes inflammation and several gastric pathologies, including gastric ulcers and gastric cancer (**Lochhead and El-Omar, 2007**).

Compelling evidence from epidemiological, histopathological and animal studies has linked *H.pylori* infection to the subsequent development of gastric cancer (**Uemura *et al.*, 2001**).

Despite the established relationship between *H. pylori* and gastric pathologies, the association between *H. pylori* and colorectal cancer is much less clear. Epidemiologic studies have used serology, PCR methods, C-urea breath tests, and circulating gastrin levels to examine colorectal neoplasia in relation to *H. pylori* infection and have produced conflicting results (**Andrea *et al.*, 2008**).

Infection of colorectal tissue with *H. pylori* may not be directly responsible for an increased risk of colorectal cancer but rather the byproducts of a gastric *H. pylori* infection (**Hartwich *et al.*, 2001**). One theory stems from the fact that gastric *H. pylori* infection increases serum

levels of gastrin leading to hypergastrinemia (**Mulholland *et al.*, 1993**). Because hypergastrinemia is hypothesized to have proliferative effects on intestinal mucosa (**Sobhani *et al.*, 1993**). A positive association has been found between hypergastrinemia and colorectal neoplasia (**Georgopoulos *et al.*, 2006**).

Carcinogenesis via *H. pylori* involves inflammation, as well as deregulation of the cell cycle via the *H. pylori* protein, cytotoxin-associated gene A (CagA), which binds and activates SHP2 (a human phosphatase that can act as an oncoprotein) resulting in cell growth and motility (**Lochhead and El-Omar, 2007**).

Associations between neoplastic colorectal lesions (adenomas and carcinomas) and *H. pylori* were based on indirect evidence such as studies correlating these lesions with increased CagA+ levels (**Hartwich *et al.*, 2001**) or increased gastrin (**Konturek *et al.*, 2002**) or, direct correlation with *H. pylori* seropositivity (**Fujimori *et al.*, 2005**). Other studies have failed to demonstrate this association based on seropositivity (**Limburg *et al.*, 2002**).

Enterohepatic helicobacters are non *H. pylori* helicobacters which naturally colonise the intestinal crypts and are often associated with diarrhea, can cause bacteraemia and systemic disease including colonisation of the biliary tract and induction of cholecystitis and hepatitis (and in some cases hepatic cancer). Immunocompromised hosts are particularly susceptible to these microorganisms (**Solnick and Schauer, 2001**).

It is possible that *Helicobacter* species are under recognized causes of infective diarrhea in humans. Helicobacters cultured from human diarrheal samples include *H. cinaedi*, *H. canis*, *H. pullorum*, *Helicobacter fennelliae*, *Helicobacter Canadensis*, *Helicobacter rappini* and other unclassified but related organisms (**Fox, 2002**).